These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 32133706)

  • 1. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
    Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
    Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling.
    Lee KY; Kuo TC; Chou CM; Hsu WJ; Lee WC; Dai JZ; Wu SM; Lin CW
    Cells; 2020 Dec; 10(1):. PubMed ID: 33375719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
    Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
    Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
    J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
    Zhang S; Ma Y; Hu X; Zheng Y; Chen X
    J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
    Zhang H; Cao Y; Tang J; Wang R
    Biomed Res Int; 2022; 2022():9944847. PubMed ID: 35813221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
    Gu X; Zhou L; Chen L; Pan H; Zhao R; Guang W; Wan G; Zhang P; Liu D; Deng LL; Zhao W; Lu C
    Biomed Res Int; 2021; 2021():6628682. PubMed ID: 33860045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
    J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-β signaling.
    Taki T; Shiraki Y; Enomoto A; Weng L; Chen C; Asai N; Murakumo Y; Yokoi K; Takahashi M; Mii S
    Cancer Sci; 2020 Dec; 111(12):4616-4628. PubMed ID: 33007133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STRIP2 is regulated by the transcription factor Sp1 and promotes lung adenocarcinoma progression via activating the PI3K/AKT/mTOR/MYC signaling pathway.
    Pan J; Zhang Y; He L; Wu Y; Xiao W; Zhang J; Xu Y
    Genomics; 2024 Sep; 116(5):110923. PubMed ID: 39191354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serous IFNA3 predicts unfavorable prognosis in lung cancer via abnormal activation of AKT signaling.
    Ge Q; Cong P; Ji Y
    IUBMB Life; 2019 Nov; 71(11):1806-1814. PubMed ID: 31419016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
    Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
    Mo XT; Leung TH; Tang HW; Siu MK; Wan PK; Chan KK; Cheung AN; Ngan HY
    Br J Cancer; 2020 Sep; 123(5):833-843. PubMed ID: 32507856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma.
    Ji Z; Pan X; Shang Y; Ni DT; Wu FL
    Tissue Cell; 2019 Dec; 61():44-50. PubMed ID: 31759406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.